ogfr polyclonal antibody  (Thermo Fisher)

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma

doi:

Figure Lengend Snippet: OGFr is expressed in HCC cells and tissues. A. OGFr mRNA expression by RT-PCR in HOSE cells, A2780 cells (ovarian cancer cells), a colon cancer cell line (HCT116 cells), and three cell lines of HCC, including HepG2, SK-Hep1 and HUH-7. B. The difference of OGFr mRNA expression levels in tumor and non-tumor tissues. Total mRNA was extracted from liver cancer, colon cancer and gastric cancer tissues for qRT-PCR. C. Hepatocellular carcinoma tissues were used to perform immunohistochemistry assays to compare the OGFr protein expression difference between tumor and non-tumor tissues. The OGFr protein expression was more pronounced and in all groups turned the non-tumor tissues a brownish color not observed in tumor tissues.

Article Snippet: OGFr knockdown was confirmed by western blot analysis with goat OGFr polyclonal antibody (Santa Cruz Biotechnology, #sc-85796).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Immunohistochemistry

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma

doi:

Figure Lengend Snippet: OGF inhibits HCC cell migration and proliferation. (A) We performed a scratch assay in a HepG2 cell line. Cells exposed to OGF migrate significantly more slowly than control cells. (B) In SK-Hep1 and HepG2 cell lines, we used a MTT assay to observe whether OGF inhibited cell proliferation. OGFr inhibits cell proliferation by upregulating p21 and p53 expression (C, D). SK-Hep1 cells were transfected with OGFr siRNA or scrambled siRNA. Proteins underwent western blotting with antibodies forp21, Cdk2, p53 and Bcl-2. GAPDH was used as the internal control. OGFr-siRNA-transfected SK-Hep1 cells showed lower expression of p21 and p53 but higher expression of Cdk2, Cdk6, and Bcl-2 than control groups.

Article Snippet: OGFr knockdown was confirmed by western blot analysis with goat OGFr polyclonal antibody (Santa Cruz Biotechnology, #sc-85796).

Techniques: Migration, Wound Healing Assay, Control, MTT Assay, Expressing, Transfection, Western Blot

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma

doi:

Figure Lengend Snippet: OGF and DDP suppressed tumor growth in animal experiments. A. We used 4 groups of HCC mice models, with 5 mice in each group. B. Here we show the resected tumors of the 4 groups of mice on day 28. The tumor volumes of the OGF group, DDP group, and OGF+DDP group are all smaller than the PBS group on day 28. C. Tumor volumes were measured every other day until the treatment ended on day 28. The tumor growth of the OGF group, DDP group and OGF+DDP group are all slower than the control group. The OGF+DDP group is the slowest. D. Tumor volume values represent means + SE for 5 mice/group. These values are significantly different from the control group at *P < 0.05, **P < 0.01 and ***P < 0.001 and from DDP at +P < 0.05, ++P < 0.01 and +++P < 0.001. E. Immunohistochemistry results of resected HCC tissues from animal models show that the OGFr, p16, p21, and p53 expression levels are higher in the OGF+DDP group than in the DDP group. F-H. Western blot results of p53 and OGFr of HCC tissues derived from animal models shows that OGF and DDP increased p53 and OGFr expression in HCC cells. However, OGF only increased p53 expression slightly. The DDP group had similar p53 expression compared with the OGF and DDP combination group. These values are significantly different from those of the control group at *P < 0.05, **P < 0.01 and ***P < 0.001.

Article Snippet: OGFr knockdown was confirmed by western blot analysis with goat OGFr polyclonal antibody (Santa Cruz Biotechnology, #sc-85796).

Techniques: Control, Immunohistochemistry, Expressing, Western Blot, Derivative Assay